Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MaaT013 with Ipilimumab and Nivolumab in Melanoma
NCT04988841Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2022
- Primary completion
- Aug 2024
- Modality
- Live Biotherapeutic Products, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 2 trial of MaaT013 in melanoma, sponsored by Assistance publique - Hôpitaux de Paris. Started Jan 2022; status: completed.
02
Drugs
MaaT013
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04988841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04988841.